Citadel Advisors’s Evotec EVO Stock Holding History

Citadel Advisors’s Portfolio EVO Stock Details EVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-87,180	Closed	-$218K	–	13987
2026 Q1	$218K	Buy	87,180 +17,665	+25%	+$56.9K	﹤0.01%	11245
2025 Q4	$214K	Sell	69,515 -26,530	-28%	-$91K	﹤0.01%	10900
2025 Q3	$349K	Buy	96,045 +62,471	+186%	+$237K	﹤0.01%	10012
2025 Q2	$141K	Buy	+33,574	New	+$132K	﹤0.01%	11012
2024 Q4	–	Sell	-27,460	Closed	-$100K	–	14736
2024 Q3	$100K	Buy	27,460 +16,016	+140%	+$63.5K	﹤0.01%	11113
2024 Q2	$54.9K	Buy	+11,444	New	+$64.2K	﹤0.01%	11654
2023 Q4	–	Sell	-25,754	Closed	-$254K	–	14529
2023 Q3	$254K	Buy	25,754 +12,254	+91%	+$144K	﹤0.01%	9472
2023 Q2	$151K	Buy	+13,500	New	+$144K	﹤0.01%	10324
2023 Q1	–	Sell	-13,284	Closed	-$107K	–	14909
2022 Q4	$107K	Buy	+13,284	New	+$116K	﹤0.01%	11117

Other funds holding EVO

DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.31B AUM 20.77% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return

Fore Capital New York $338M AUM 10.07% 1-Year Est. Return

Citadel Advisors's EVO Position: Q2 2026 in Review

Citadel Advisors sold out of Evotec (EVO) in Q2 2026, closing a stake of 87,180 shares — an estimated $218K sold.

Citadel Advisors first reported a position in EVO in Q4 2022 and held it in 9 quarters. The position peaked at $349K in Q3 2025. 34 funds tracked by Wall St. Rank hold EVO as of Q2 2026.

Citadel Advisors reported no remaining Evotec position as of Q2 2026 after selling out during the quarter.
Citadel Advisors sold 87,180 Evotec shares in Q2 2026, an estimated $218K.
Citadel Advisors first reported a position in Evotec in Q4 2022 and held it in 9 quarters.
Citadel Advisors's Evotec position peaked at $349K in Q3 2025.
34 funds tracked by Wall St. Rank held Evotec as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.